tbuckley/cabot-search huggingface dataset:
Prognostic role of lymph node status in primary advanced ovarian cancer after complete resection or residual disease less than 1 cm: Results of a meta-analysis of the AGO-OVAR meta-database.
Authors: P. Harter, A. Reuss, J. Pfisterer, E. Pujade-Lauraine, I. L. Ray-Coquard, A. Du Bois
Journal: Journal of Clinical Oncology (2010)

5048 Background: The role of lymphadenectomy (LNE) in advanced ovarian cancer is still under discussion and actual randomised trials (LION) are ongoing. Positive lymph node status is a poor prognostic factor in early ovarian cancer, however, its role in advanced ovarian cancer is less clear. Methods: Exploratory analysis of three prospectively randomized trials (AGO- OVAR 3, 5, and 7) investigating platinum-taxane based chemotherapy regimens in advanced ovarian cancer (AOC) (FIGO IIB-IV) conducted 1995-2002 including 3388 pts. Uni- and multivariate analysis of the impact of lymph node status on survival in a large patient cohort with homogeneous state-of-the-art systemic therapy after primary debulking surgery with residual tumor less than 1cm and LNE. Results: Of 1,048 pts with LNE and small residual disease < 1 cm, 610 pts (58.2%) had a pelvic and para-aortic LNE and 438 pts (41.8%) had received a less systematic LNE. 658 pts (62.8%) had complete resection and 390 pts (37.2%) had residuals < 1 cm after surgery. 547 pts (52.2%) had lymph node metastasis. Pathologic lymph node status showed a significant impact on survival regardless of further prognostic factors (e.g., residual tumor) in all pts and any type of LNE. The survival was longest in pts with pathologically negative nodes and no gross residual tumor (median 109 months, 5-YSR 72.8%) and shortest in patients with small residual disease (< 1 cm) and pathologically positive nodes (median 37 months, 5-YSR 28.2%). The absolute loss regarding median survival by lymph node metastasis was 33 months (95% CI: 10-50 months) in patients without and 11 months (95% CI: 0·5-20 months) in patients with small residual tumor. Conclusions: Positive lymph nodes alter prognosis at least in patients with AOC and palpable lymph nodes. The role of LN status and LNE in patients with clinically negative nodes and subsequent systematic LNE will be answered by the ongoing LION trial. No significant financial relationships to disclose.
Treatment of interstitial pneumonia in cancer patients: is empiric antibiotic therapy the answer?
Authors: C I Bustamante, J C Wade
Journal: Journal of Clinical Oncology (1990)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1990.8.2.200 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2299366 Treatment of interstitial pneumonia in cancer patients: is empiric antibiotic therapy the answer? C I BustamantexC I BustamanteSearch for articles by this author , J C WadexJ C WadeSearch for articles by this author https://doi.org/10.1200/JCO.1990.8.2.200 First Page PDF © 1990 by American Society of Clinical Oncology
Carcinogenicity of N -Nitrosodiethylamine in Hibernating and Nonhibernating European Hamsters 2
Authors: Gerd Reznik, Hildegard Reznik-Schüller, Ulrich Mohr
Journal: JNCI Journal of the National Cancer Institute (1977)

Hibernating European hamsters reacted differently to sc injections of N-nitrosodiethylamine (DEN) than did European hamsters that were not hibernating. Hibernating animals tolerated higher dose levels but developed fewer neoplasms. In contrast, hibernating males had more pulmonary tumors than did the respective nonhibernators. However, the hibernating females of the low dosage group developed fewer lung tumors. The survival times were longer for the male hibernators than for the male nonhibernators. The organ specificity of DEN, as well as the morphology and histogenesis of the neoplasms, showed no differences between the hibernating and nonhibernating groups.
The difference between the subjective and objective evaluation of oxaliplatin-induced vascular pain due to administer chemotherapy via peripheral vein.
Authors: Naoya Aisu, Yoichiro Yoshida, Teppei Yamada, Taisuke Matsuoka, Daibo Kojima, Syu Tanimura, Seiichiro Hoshino, Ai Mogi, Tomoko Koganemaru, Mayumi Oda, Mahiru Fukuda, Fumiaki Kiyomi, Keita Noda, Keiji Hirata, Kazuo Tamura, Yuichi Yamashita
Journal: Journal of Clinical Oncology (2015)

651 Background: We have reported the safety and effectiveness of chemotherapy via median cubital vein for metastatic colorectal cancer without implantation of a central venous port. However, vascular pain (VP) occasionally requires switching of the drip infusion route during chemotherapy for the administration of oxaliplatin via the peripheral vein. VP and phlebitis induced by intravenous infusion of antineoplastic agents reduces the rate of completion or continuation of chemotherapy. We also reported that addition of dexamethasone to oxaliplatin drip infusion controlled the vascular pain caused by administration of oxaliplatin via the peripheral vein (ASCO-GI2012). Pain is currently evaluated using subjective methods such as the visual analog scale (VAS). However, because the assessment of pain can greatly vary depending on the mood and physical state of the patient at the time of assessment, it is best to objectively evaluate pain. Pain Vision PS-2100 (PV) is an analytical instrument that was designed to quantitatively and objectively assess sense perception and nociception in a patient. Although it is used in the field of anesthesiology, there have been no reports concerning it for the assessment of oxaliplatin-induced VP. Methods: The present study examined the correlation of subjective and objective assessment results using VAS and PV, respectively, for cases of oxaliplatin-induced VP. Subjects comprised 57 patients with colorectal cancer who underwent chemotherapy at the Fukuoka University. Results: Both VAS and PV assessments of PN were performed 162 times in total, and partial correlation coefficient analysis adjusted by subject and gender. The VAS and PV mean values of VP were 24.8 (0–100) and 44.5 (0–596), respectively. The partial correlation coefficient was 0.350 (p= 0.0002). Conclusions: Although both assessments evaluated the same events, no strong correlation was observed between the results and a weak correlation was observed between VAS and PV. These results suggest that because VAS and PV each measure different factors, both subjective and objective assessments of drugs designed to ameliorate oxaliplatin-induced VP are necessary.
Response, time to progression, and overall survival of patients with stage III lung cancer in a minority-based cohort
Authors: R. Kouz, S. Sreenivasappa, K. Adab, B. Ciobanu, S. Ofori, M. Shah, M. Kassem, L. Hussein, T. Lad
Journal: Journal of Clinical Oncology (2009)

7558 Background: Lung cancer is the leading cause of cancer death. Response and survival of patients (pts) with stage III lung cancer in minority population is not well studied. Methods: 79 pts treated between 2001 and 2006 were studied as a retrospective cohort. Clinical and survival data were analyzed using fisher's test, chi square test, Kaplan Meier analyses. Results: 33 Pts had Stage IIIA; Median age at diagnosis was 58 yrs (37–75). 14 were males (42.4%) 19 females (57.6%) 26 African American (78.8%) and 7 Caucasians (21.2%). Median number of co morbidities 2 (0–4). Mean follow up was 25 months (mo) (2 - 93), 19 had surgery (12 Lobectomy (36.4%), 7 Pneumonectomy (21.2%)) and 14 were unresectable (42.4%). All pts received adjuvant chemotherapy. Unresectable pts received chemotherapy and radiation, 8 carboplatin and gemcitabine and 6 cisplatin and etoposide. Median time to progression in resectable IIIA was 23 mo (2- 67), unresectable IIIA was 12 mo (3–93). Median survival in pts with resection was 26 mo (2 - 67), unresectable was 12 mo (5 - 93). Overall survival and time to progression was not influenced by sex, race, tumor type. 46 pts had stage IIIB, median age at diagnosis 57.5 yrs (40–68). 31 were males (67.4%) 15 females (32.6%) 29 African Americans (63%) 11 Caucasians (23.9) 3 Asians (6.5%) and 3 Hispanics (6.5%). Median follow up was 10 mo (3–97). All pts received chemotherapy and radiation. 23 received cisplatin and etoposide (50%), 14 carboplatin and gemcitabine (30%), 5 carboplatin and etoposide (9%), 5 carboplatin and paclitaxel (9%). 13 had complete response (28.3%), 15 partial response (32.6%), 2 stable disease (4.3%) and 10 Progression (21.7%). Median time to progression was 9 mo (3–97). Median overall survival was 10 mo (3–97). Overall survival and time to progression was not influenced by sex, race, tumor type, chemotherapy regimen. Conclusions: In this minority based cohort response, time to progression, overall survival in both IIIA and IIIB pts is much lower then historical controls. The overall survival and time to progression in both IIIA and IIIB is not influenced by race, sex, tumor type and type of chemotherapy regimen. Further investigations of disease and healthcare disparities in the underserved minority population, are warranted. No significant financial relationships to disclose.
Adaptive servoventilation reduces the risk of malignant arrhythmic events in patients with congestive heart failure and Cheyne-Stokes respiration
Authors: Thomas Bitter, Nina Westerheide, Georg Nölker, Klaus-Jürgen Gutleben, Jürgen Vogt, Johannes Heintze, Dieter Horstkotte, Jost Niedermeyer, Olaf Oldenburg
Journal: European Respiratory Journal (2011)

Cheyne-Stokes respiration (CSR) is an independent risk factor for malignant arrhythmias in patients (pts) with congestive heart failure (CHF). The aim of this study was to investigate whether treatment of CSR with Adaptive Servoventilation (ASV) reduced the risk of malignant arrhythmic events in pts with CHF.

403 pts with CHF (LVEF ≤ 45%, NYHA-class ≥ 2) and an implanted CRT-D or ICD device underwent overnight polygraphy with 221 having mild or no CSR (Apnea Hypopnea Index (AHI)   15/h). Those with CSR were offered therapy with ASV accepted by 96 and rejected by 86 pts. During follow-up (48 months) CRT or ICD monitored ventricular arrhythmias and cardioversion events were recorded in addition to clinical and physiologic measures of heart failure severity.

Event-free survival from a) appropriately monitored ventricular arrhythmias and b) appropriate cardioverter-defibrillator therapies was shorter in the untreated CSR group compared to the treated CSR and the no CSR group. Stepwise Cox proportional hazard regression analysis showed untreated CSR (a: HR 1.99, 95%CI 1.46-2.72, p<0.001; b: HR 2.19, 95%CI 1.42-3.37, p<0.001), but not treated CSR (a: HR 1.06, 95%CI 0.74-1.50; p=0.77; b: HR 1.21, 95%CI 0.75-1.93, p=0.43) was an independent risk factor.

Conclusion: In pts with CHF and CRT/ICD the presence of untreated CSR is a risk factor for malignant arrhythmias. Treatment of CSR with ASV mitigates the risk. If present, CSR appears a therapeutic target for pts with CHF at risk of malignant arrhythmias.
Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer (HRPC)
Authors: E. J. Small, P. F. Schellhammer, C. S. Higano, J. Neumanaitis, F. Valone, R. Hershberg
Journal: Journal of Clinical Oncology (2005)

4500 Background APC8015 is an immunotherapy cellular product consisting of autologous peripheral blood mononuclear cells enriched for a dendritic cell fraction pulsed with PA2024, a Prostatic Acid Phosphatase (PAP)-GM-CSF construct. We previously reported results including time to objective progression (TTP) and time to onset of disease related pain (TDRP) from a randomized trial in metastatic HRPC. Reported here are final overall survival (OS) data from this trial, as well as results of immunologic testing. Methods Patients (pts) with asymptomatic, metastatic HRPC were randomized (2:1) to receive APC8015 (n=82) or placebo (n=45) every 2 weeks x 3. Eligible pts had > 25% of cancer cells positive for PAP by central pathology review. The primary endpoint was TTP. TDRP was a secondary endpoint and pts were monitored for OS at 36 months. Monitoring was by weekly pain logs and serial radiologic imaging. Progression and pain were centrally reviewed and pts were followed per protocol for survival for 3 years following randomization. T-cell proliferation to PA2024 was evaluated by 3H-thymidine uptake. The T-Cell Stimulation Index (TCSI) was defined as: counts per minute (cpm) with antigen/cpm without antigen. The TCSI-ratio was defined as the median TCSI at 8 weeks/median TCSI at pre-treatment. Results 127 pts were randomized between 1/00 and 10/01. In an intent-to-treat (ITT) analysis, median OS was 25.9 months for pts on APC8015 compared with 22.0 months for those on placebo (p=0.020, log-rank, hazard ratio 1.625). At 36 months, 33% of APC8015 pts were alive, compared with 11% of placebo pts. The TCSI-ratio was 16.9 for APC8015 and 1.99 for placebo (p=.003, Wilcoxon Rank Sum). Treatment was generally well tolerated. Grade 1 and 2 fevers and rigors were the most common treatment-related AEs. Conclusions In an ITT analysis, treatment with APC8015 resulted in a statistically significant OS advantage of 3.9 months in pts with asymptomatic HRPC, representing the first survival advantage attributed to an immunotherapy product in prostate cancer. APC8015 pts also had an 8-fold increase in the TCSI-ratio. These data support this approach in the treatment of pts with metastatic HRPC. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Dendreon Dendreon Dendreon Dendreon Dendreon Dendreon
Effect of Antimetabolites on Kinetic Behavior of Proliferating Cultured L1210 Leukemia Cells&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: L. J. Wilkoff, W. S. Wilcox, J. A. Burdeshaw, G. J. Dixon, E. A. Dulmadge
Journal: JNCI Journal of the National Cancer Institute (1967)

The effect of amethopterin, 5-fluorouracil, 1-β-D-arabinofuranosylcytosine hydrochloride, and azaserine on the kinetic behavior of proliferating cultured L1210 leukemia cells was studied. Leukemia L1210 cells proliferating in vitro were exposed to selected drug concentrations for different periods and the number of cells surviving drug treatment was estimated by an animal. bioassay method. The cultured L1210 populations exhibited two distinct types of kinetic behavior relating to the rate of cell killing: 1) In L1210 populations treated with amethopterin,5-fluorouracil, and 1-β-D-arabinofuranosylcytosine hydrochloride, the rate of cell killing deviated from first-order kinetics. (The kinetics.could be described by a Gompertz equation of the form N = N0e-β/α(1-e-αt) where N0 is the number of viable cells present at time zero, N is the number of viable cells present at time t, t is the duration of drug exposure, β is the rate of population reduction, and a is a constant which expresses the rate of change of β.) The rate of population reduction appeared to depend, at least partly, on .the metabolic heterogeneity of the cell populations. 2) In L1210 cell populations treated with azaserine, the rate of viable. cell reduction followed first-order kinetics. In this case, a is not significantly different from zero, and the Gompertz equation reduces to N = N0e-βt which is the first-order rate equation. The rate of cell killing appeared to be independent of the metabolic heterogeneity of the cell populations.
Somatic Mutation Spectrum in Monoclonal Gammopathy of Undetermined Significance Compared to Multiple Myeloma
Authors: Aneta Mikulasova, Brian A Walker, Christopher P Wardell, Eileen M Boyle, Alexander Murison, Zuzana Kufova, Ludek Pour, Petr Kuglik, Roman Hajek, Gareth J. Morgan
Journal: Blood (2014)
Abstract 12525: Association of Endothelium-dependent Coronary Vasomotor Response and Neointimal Coverage of Zotarolimus-Eluting Stents Three Months After Implantation
Authors: Kenichi Fujii, Daizo Kawasaki, Hirokuni Akahori, Tsuyoshi Nakata, Masashi Fukunaga, Hisashi Sawada, Motomaru Masutani, Masaaki Lee-Kawabata, Takeshi Tsujino, Mitsumasa Ohyanagi, Tohru Masuyama
Journal: Circulation (2010)

Background: Recent studies reported that zotarolimus-eluting stents (ZES) had a higher rate of neointimal coverage than the first-generation drug-eluting stents on optical coherence tomography (OCT...
Swallowing disorders and speech rehabilitation in tracheostomized difficult-to-wean patients
Authors: Guido Vagheggini, Adriano Di Paco, Giuseppa Pullarà, Anna Bartolini, Monica Orlandini, Eugenia Panait Vlad, Nicolino Ambrosino
Journal: European Respiratory Journal (2011)

Background: Swallowing disorders often complicates long-term management of tracheostomised difficult-to wean patients (DWPs) and may represents a common drawback to the removal of the cannula.

Aim: To evaluate the prevalence of swallowing disorders among DWPs and the restoration of proper swallowing after a weaning and pulmonary rehabilitation program including speech rehabilitation (SR).

Methods: 157 tracheostomised DWPs (83 males, age 69.9±12.5y), consecutively admitted, underwent dysphagia assessment including objective assessment, methylene blue test, and eventually fibroschopy swallowing evaluation.

Results: 74 patients (42 males, age: 70.9±12.6y), were evaluated at risk of aspiration, and underwent SR program. 25 patients, affected by severe ALS, and 13 affected by neurological disorders determining very severe cognitive impairment (GCS<9) were not included in the SR program. 57 (77.0%) out of 74 treated patients recovered swallowing function and were allowed to feed orally; 8 (10,8%) semiliquid, 17 (23.0%) semisolid; 14 (18,9%) homogeneous; 18 (24,3%) solid. In 10 patients compensatory postures were adopted. 13 patients were treated with percutaneous gastro/jejunostomy, 4 were discharged with nasogastric feeding tube. 30 patients (40.5%) underwent to tracheostomy decannulation. Length of stay was greater for dysphagic patients (21,7±12,7 vs 33,5±14,4; p<0.001).

Conclusions: Swallowing disorders showed high prevalence among DWPs and are related to an higher length of stay in hospital. Further research are needed in order to determine the burden of swallowing disorders in DWPs and evaluate the effectiveness of their treatment.
Canonical genetic signatures of the adult human brain
Authors: Michael Hawrylycz, Jeremy A Miller, Vilas Menon, David Feng, Tim Dolbeare, Angela L Guillozet-Bongaarts, Anil G Jegga, Bruce J Aronow, Chang-Kyu Lee, Amy Bernard, Matthew F Glasser, Donna L Dierker, Jörg Menche, Aaron Szafer, Forrest Collman, Pascal Grange, Kenneth A Berman, Stefan Mihalas, Zizhen Yao, Lance Stewart, Albert-László Barabási, Jay Schulkin, John Phillips, Lydia Ng, Chinh Dang, David R Haynor, Allan Jones, David C Van Essen, Christof Koch, Ed Lein
Journal: Nature Neuroscience (2015)
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).
Authors: Franco Cavalli, Brendan Rooney, Lixia Pei, Helgi Van De Velde, Tadeusz Robak
Journal: Journal of Clinical Oncology (2014)

8500 Background: R-CHOP is standard therapy for newly diagnosed, BMT-ineligible MCL pts. Bortezomib (V) is approved in the US for relapsed MCL. This study evaluated whether replacing vincristine with V in R-CHOP improves outcomes in newly diagnosed, BMT-ineligible MCL pts (NCT00722137). Methods: Adults with treatment-naive, measurable stage II–IV MCL and ECOG PS 0–2 were randomized 1:1 (stratified by IPI score and disease stage) to 6–8 21-d cycles of rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, all IV d 1, and prednisone 100 mg/m2 PO d 1–5, plus V 1.3 mg/m2 IV d 1, 4, 8, 11 (VR-CAP) or vincristine 1.4 mg/m2(max 2 mg) IV d 1 (R-CHOP). Primary endpoint was PFS by independent radiology review (IRC); secondary endpoints included TTP, TTNT, OS, response by modified IWRC criteria, and safety. 486 pts were planned for 295 total PFS events, to provide 80% power (α=.05, 2-sided) to detect 40% PFS improvement with VR-CAP. Results: 487 pts were randomized (244 R-CHOP, 243 VR-CAP; median age 66 yrs, 74% male, 74% stage IV MCL, 54% IPI ≥3). Pts received a median of 6 cycles. After 40 mos’ median follow-up (298 PFS events), median PFS by IRC was 14.4 (R-CHOP) vs 24.7 mos (VR-CAP) (ITT analysis: HR=.63* [.50, .79], P<.001**). Secondary efficacy data are below. Rates of grade ≥3 AEs were 85% (R-CHOP) vs 93% (VR-CAP), serious AEs 30% vs 38%, discontinuations due to AEs 7% vs 9%, and on-treatment drug-related deaths 3% vs 2%. Conclusions: VR-CAP significantly prolonged PFS and consistently improved secondary efficacy endpoints vs R-CHOP in newly diagnosed, BMT-ineligible MCL pts, with additional but manageable toxicity. Clinical trial information: NCT00722137. Median outcomes, mos R-CHOP VR-CAP HR* P** PFS Investigator 16.1 30.7 .51 <.001 TTP IRC 16.1 30.5 .58 <.001 Investigator 16.8 35.0 .47 <.001 TTNT 24.8 44.5 .50 <.001 OS 56.3 NR .80 .173 4-yr OS, % 54 64 – – OR‡ P§ CR+CRu, % IRC† 41 48 1.4 .075 Investigator 28 42 1.9 .002 * Stratified Cox model (HR <1 favors VR-CAP). ** Stratified log-rank test. † Bone marrow and LDH verified. ‡ Stratified Mantel-Haenszel estimate (OR >1 favors VR-CAP). § Stratified Cochran-Mantel-Haenszel X2 test.
Phase I dose escalation study on DRF 7295: A novel peptide based anticancer drug, in patients with advanced, metastatic adenocarcinomas: Final results
Authors: D. Raghunadharao, D. C. Doval, A. Majumdar, A. Roy, S. Ganguly, G. Uppal, R. Mukherjee, A. C. Burman, N. Saha
Journal: Journal of Clinical Oncology (2004)

3094 Background: DRF 7295 is a novel combination of 4 synthetic neuropeptide analogues having antiproliferative, antiangiogenic and proapoptotic properties. It has exhibited potent preclinical activity in adenocarcinoma cell lines Preliminary Ph-I results have been published in ASCO 2003 (abstract no.948). The final results are presented herewith.Methods: 7 recurrent/metastatic adenocarcinoma patients were given escalating doses of DRF 7295 twice daily for one cycle of 21 days starting from 1.3 mg/m2. Single patient cohorts (Modified Fibonacci Method) were used for dose escalation in the absence of any dose limiting toxicities (DLTs). As no DLT was seen even at the highest dose of 11.7 mg/m2, the dose of 9.1 mg/m2 was selected as the cohort expansion dose and 9 patients were further treated at this dose (total=16).Results: There were 11 adverse drug reactions observed. No Grade 3 or 4 toxicities were seen. Most common ADRs included hot flushes (n=5, Grade1), transient fall in blood pressure (n=3, Grade 1) and mild urticaria (n=1, Grade 1), the duration and intensity of these reduced with subsequent doses. Of the 6 pts evaluable for response at the cohort expansion dose of 9.1 mg/m2, 4 had stable disease (67%) at the end of therapy of which 2 maintained their response 1-month post therapy. All responses were observed in metastatic colorectal cancers. Conclusions: DRF 7295, is a well tolerated anticancer drug devoid of toxicities commonly seen with cytotoxic drugs and may have a promising role in disease stabilization in colorectal cancer. Phase-II and combination studies with the drug have been planned. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Dabur Research Foundation Dabur Research Foundation Dabur Research Foundation
제5차 대한간학회 춘계학술대회 초록집 : 포스터 전시 순서 ; 간내 결절성 병변을 동반한 과호산구 증후군의 1예
Authors: 이경태 ( Lee Gyeong Tae ), 양현웅 ( Yang Hyeon Ung ), 서승원 ( Seo Seung Won ), 성재규 ( Seong Jae Gyu ), 이상우 ( Lee Sang U ), 이승민 ( Lee Seung Min ), 이병석 ( Lee Byeong Seog ), 김남재 ( Kim Nam Jae ), 이헌영 ( Lee Heon Yeong )
Journal: Clinical and Molecular Hepatology (1999)